AGP Executive Report
Last update: 8 hours agoDiabetes Research Clash in New Orleans: Police escorted UW diabetes experts and other scientists out of the American Diabetes Association conference after they handed out an editorial criticizing Trump-era biomedical research cuts, raising fresh alarms about how politics is colliding with STEM meetings. FDA Abortion Pill Safety Review: The FDA launched a safety study of mifepristone, with officials saying work has been underway for months—an effort that could shape future distribution rules. Obesity Drug Pipeline at ADA: Multiple Louisiana-linked biotech announcements and ADA presentations highlighted next-gen metabolic therapies, including saRNA obesity work from Ractigen, oral and injectable GLP-1/GIP and amylin-based approaches from Biomea Fusion, Hengrui/Kailera, Oban BioPharma, and others—most focused on weight loss plus preserving lean muscle. Coastal Resilience Science: Tulane research reports global mangrove forests are rebounding, offering a hopeful signal for climate and coastal protection. Louisiana Digital Access: ConnectLA launched the ÉTOUFFÉE grant to help community groups provide devices and digital skills training statewide. Public Health Watch: New Orleans mosquito surveillance found West Nile virus, and helicopter spraying was scheduled in multiple neighborhoods. Local Tech & Infrastructure: A Louisiana data center cooling patent lawsuit landed in federal court, while Louisiana’s broadband office continues pushing device-and-skills programs to close the digital divide.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
